Okogen Inc is a clinical stage ophthalmic pharmaceutical company based in Encinitas, CA. They are dedicated to enhancing lives through better vision by developing innovative treatments for acute infectious conjunctivitis, including both bacterial and viral forms. With their lead product in Phase 2B clinical trials, Okogen aims to revolutionize the pink eye treatment landscape and address the significant market demand for effective solutions.
As a leader in the field, Okogen recognizes the widespread impact of infectious conjunctivitis, which represents a substantial portion of the global conjunctivitis market. With a focus on providing comprehensive treatment options, they are committed to addressing the unmet medical needs, particularly in the case of adenoviral conjunctivitis, for which there are currently no approved treatments available. Through their research and development efforts, Okogen strives to make a significant difference in the lives of individuals affected by this common eye condition.
Generated from the website